Connecticut-based dermatology-focused biotech Veradermics held an initial public offering (IPO) to the New York Stock Exchange (ticker: MANE), releasing just over 15 million shares priced at USD 17.00 for a USD 256 million gross raise. Of note, the firm’s SEC filing indicated that Eli Lilly & Co., had indicated it will purchase a 4.9% stake at the IPO launch price.
Veradermics is developing VDPHL01, an oral extended-release formulation of minoxidil, to treat pattern hair loss by maximizing hair-growth efficacy while minimizing cardiac risk compared with immediate-release oral minoxidil. Minoxidil is a vasodilator that has been used for many years in topical formulation that widens blood vessels, improving follicle circulation and extending the hair’s growth (anagen) phase.
Veradermics’ proprietary ER design aims to sustain plasma levels that enhance follicular exposure without inducing cardiac activity, building on minoxidil’s well-validated hair growth biology. The company is running a registration-directed clinical program of three pivotal, randomized, placebo-controlled trials—two in men and one in women—to support a 505(b)(2) FDA submission. The first Phase II/III trial, now fully enrolled, is evaluating two VDPHL01 dose regimens in 519 men with mild-to-moderate PHL over 52 weeks.
Veradermics is not alone in targeting PHL, with a recent surge in clinical development activity and a diverse array of new modalities and mechanisms. Other small molecule drugs under target androgen receptor inhibition, prostaglandin modulation, Wnt/β-catenin pathway activation, and immunomodulation. Key assets include topical therapies from Cosmo Pharmaceuticals, Eirion, and Palage Therapeutics.